reported FGF2 immunostaining in Bowman’s capsule, the glomerular, mesangium, blood vessels, and the interstitium, as well as some tubules in rats, FGF-2 was synthesized by mesangial cells in vitro and in vivo. įGF-2 protein was isolated from the kidney in 1985.
FGF2 displays a potent capacity to induce tubuloepithelial cell plasticity and promote renal fibroblasts proliferation, and its expression is significantly increased in human kidney disease with marked fibrosis. įibroblast growth factor-2 (FGF2) is a key fibrogenic cytokine that is likely to be involved in the pathogenesis of renal fibrosis. Ī key role in tubulointerstitial fibrosis is the tubular epithelial-to-mesenchymal transition (EMT), or transdifferentiation of tubular epithelial cells into myofibroblasts, which are the cells responsible for the secretion and accumulation of extracellular matrix components. Numerous studies have provided experimental evidence that tubuloepithelial cell plasticity and interstitial fibroblast proliferation contribute to the accumulation of interstitial fibroblasts in the renal parenchyma. ĭeposition of extracellular matrix components and interstitial fibroblast accumulation are two main features of tubulointerstitial fibrosis. Renal tubulointerstitial fibrosis is a structural marker and prominent pathological characteristic of chronic progressive kidney disease, and the degree of tubulointerstitial scarring is an excellent prognostic marker for end-stage renal disease. FGF-2 and KIM-1 are expected to be therapeutic targets for kidney injury. It may become a useful biomarker without the need for the invasive maneuver of the renal biopsy. Serum FGF-2 and KIM-1 seem to be a non-invasive novel biomarker of interstitial renal fibrosis in glomerulonephritis patients. there is a positive significant correlation between serum KIM-1 and FGF-2 and hypertension with a significant P value (<0.001) that serum KIM-1 has sensitivity 90% and specificity of 95% and serum FGF-2 has sensitivity 95% and specificity 95% for detection of interstitial renal fibrosis. We found a significant positive correlation between FGF-2 and KIM-1 and the degree of interstitial renal fibrosis, albumin, and creatinine ( P≤ 0.001), and a negative significant correlation with GFR and proteinuria. We prospectively enrolled a cohort study of eighty adult patients who had glomerular diseases (with glomerular filtration rate (GFR) > 30 ml/min/m 2) serum level of FGF-2 and KIM-1 was measured at the same time of renal biopsy and was correlated with the degree of interstitial renal fibrosis. It is believed that this molecule participates in the process of both kidney injury and healing. Santa Cruz Biotechnology FGF-2 antibody (santa Cruz, sc-365106) was used in immunohistochemistry - frozen section on rat samples at 1:300 (fig 4).Renal tubulointerstitial fibrosis is a structural marker and prominent pathological characteristic of chronic progressive kidney disease, fibroblast growth factor-2 (FGF2) is a key fibrogenic cytokine that is likely to be involved in the pathogenesis of renal fibrosis, kidney injury molecule-1 (KIM-1) is one of the most promising, early biomarkers of renal disease, either acute or chronic, due to its translatability between preclinical and clinical trials. immunohistochemistry - frozen section rat 1:300 fig 4.Santa Cruz Biotechnology FGF-2 antibody (Santa Cruz, sc-271847) was used in western blot on rat samples at 1:1000 (fig 5). In order to study B-type natriuretic peptide knock-out females for arterial remodeling, Santa Cruz Biotechnology FGF-2 antibody (Santa Cruz, sc-365106) was used in immunohistochemistry - frozen section on rat samples (fig 2). immunohistochemistry - frozen section rat fig 2.
Santa Cruz Biotechnology FGF-2 antibody (Santa Cruz, sc-74412) was used in western blot on human samples (fig 2). Santa Cruz Biotechnology FGF-2 antibody (Santa Cruz, sc-271847) was used in western blot on mouse samples at 1:1000 (fig 2e, 2f). Santa Cruz Biotechnology FGF-2 antibody (Santa Cruz Biotechnology, SC-365106) was used in western blot on mouse samples at 1:500 (fig 1d). Santa Cruz Biotechnology FGF-2 antibody (Santa Cruz, sc-365106) was used in western blot on mouse samples (fig 6a). Santa Cruz Biotechnology mouse monoclonal (G-2)
0 kommentar(er)
